COMMUNIQUÉS West-GlobeNewswire
-
Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at Scripps’ Structural Heart Intervention and Imaging 2026 Conference
05/02/2026 -
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
05/02/2026 -
In a Defining Election Year, MAPS Releases Policy Guidebook to Shape the Future of Psychedelic Reform
05/02/2026 -
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
05/02/2026 -
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
05/02/2026 -
Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board
05/02/2026 -
ADARx Pharmaceuticals Appoints Donald Fong, M.D., as Chief Medical Officer
05/02/2026 -
Polaryx Therapeutics Welcomes New Members of the Board of Directors
05/02/2026 -
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
05/02/2026 -
Vistin Pharma ASA (VISTN): Invitation to Q4 2025 conference call
05/02/2026 -
Aclarion Publishes 2026 Shareholder Letter from the Chairman
05/02/2026 -
Aicuris Presents Positive Phase 3 Data for Pritelivir in Immunocompromised Patients with Refractory Herpes Simplex Virus at TANDEM
05/02/2026 -
EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB
05/02/2026 -
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
05/02/2026 -
Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary
05/02/2026 -
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
05/02/2026 -
Biocomposites gains MDR certification for STIMULAN® Rapid Cure and STIMULAN® Kit
05/02/2026 -
Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation
05/02/2026 -
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
05/02/2026
Pages